Physician profile
Arash Nowain
NPI 1003084120
$5,169.98
in general payments reported to CMS, 2019-2025
23 companies · $813 in 2025
The $813 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $170 · 2021: $424 · 2022: $906 · 2023: $914 · 2024: $1,151 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831 · Education: $47.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.03 |
| Education | $47.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,483.74 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $751.28 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $726.33 | 2019-2024 | Winlevi |
| Takeda Pharmaceuticals U.S.A., INC. | $505.15 | 2023-2025 | Entyvio |
| Shire North American Group INC | $500.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $176.93 | 2022-2024 | Dupixent |
| Genzyme Corporation | $153.78 | 2023-2025 | |
| Journey Medical Corporation | $116.00 | 2022-2025 | |
| Janssen Biotech, INC. | $109.41 | 2022-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $106.63 | 2023-2024 | Linzess |
| Epi Health, LLC | $93.21 | 2019-2021 | |
| Capsovision, INC. | $69.82 | 2025 | Capsocam Plus |
| Leo Pharma INC. | $63.11 | 2019-2021 | |
| Ardelyx, INC. | $62.92 | 2025 | Ibsrela |
| Incyte Corporation | $46.09 | 2025 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $45.34 | 2024-2025 | Voquezna |
| Medtronic, INC. | $36.15 | 2021-2024 | Bravo |
| Braintree Laboratories, INC. | $25.70 | 2024 | Sutab, Suflave |
| Mission Pharmacal Company | $24.96 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.40 | 2019 | |
| Almirall LLC | $23.30 | 2019 | |
| Concordia Pharmaceuticals INC. | $14.48 | 2019 | |
| Dermira, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Nowain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.